Scripps Research Names Jin-Quan Yu to Newly-Endowed Bristol Myers Squibb Chair in Chemistry
Scripps Research Names Jin-Quan Yu to Newly-Endowed Bristol Myers Squibb Chair in Chemistry
Bristol Myers Squibb (NYSE: BMY) and Scripps Research today announced that Bristol Myers Squibb has endowed a chair in chemistry at Scripps Research to advance scientific research critical to drug discovery.
布里斯托尔·迈尔斯奎布（紐約證交所:BMY）和斯克里普斯研究公司今天宣布布里斯托爾·邁爾斯·施奎布（Bristol Myers Squibb）在斯克里普斯研究中心授予化學主席，以推進對藥物發現至關重要
Scripps Research has named Professor Jin-Quan Yu, PhD , a pioneering chemist whose research has paved the way to powerful new techniques used in fields ranging from drug discovery to materials science, to be the inaugural holder of the Bristol Myers Squibb Endowed Chair in Chemistry.
斯克里普斯研究所命名余金泉教授博士，他是一位先鋒化學家，他的研究已為從藥物發現到材料科學領域使用的強大新技術鋪平了道路，成為布里斯托爾邁爾斯 Squibb 化學講座主席的首任持有人。
“Bristol Myers Squibb and Scripps Research have had a long-standing relationship and we are proud to endow this chair to support transformative research with unrestricted funding,” said Rupert Vessey , M.A., B.M., B.Ch., F.R.C.P., D.Phil., Executive Vice President and President, Research & Early Development, Bristol Myers Squibb. “We look forward to further groundbreaking chemistry to emerge from Scripps Research.”
布里斯托爾邁爾斯·斯奎布執行副總裁兼研究與早期開發總裁魯珀特·維西（Rupert Vessey）表示：「布里斯托爾·邁爾斯·斯奎布和斯克里普斯研究公司建立了長期的關係，我們很自豪能夠賦予這張椅子，以支持變革性研究，無限制的資金。「我們期待著進一步突破性化學從斯克里普斯研究中出現。」
“Academic research serves as a wellspring for advancements in medicine,” said Peter Schultz, PhD, president and CEO of Scripps Research. “Looking at how a drug can progress from a discovery in our labs to an approved medicine for patients, it becomes clear that effective translation of academic discoveries to biopharma is essential for tackling the world’s health challenges.”
斯克里普斯研究公司總裁兼首席執行官彼得·舒爾茨（Peter Schultz）博士說：「學術研究是醫學進步的源泉。「研究一種藥物如何從我們實驗室中的發現發展到為患者提供批准的藥物，很明顯，有效地將學術發現轉換為生物製藥對於應對世界健康挑戰至關重要。」
Schultz continued, “The new $3 million chair endowed by Bristol Myers Squibb can help to support the next generation of biomedical breakthroughs by providing sustained, unrestricted funding to support research programs. Jin-Quan’s creative insights and unconventional approach to organic synthesis have already transformed chemical processes used for developing new medicines and many other products that can impact people’s lives around the globe.”
Schultz 繼續說道，「布里斯托爾·邁爾斯·斯奎布（Bristol Myers Squibb）授予的新 $3 萬主席可以通過提供持續的支持，不受限制的資金來支持研究計劃來幫助支持下一代生物醫學的突破。Jin-Quan 在有機合成方面的創造性見解和非常規方法已經改變了用於開發新藥和許多其他產品的化學過程，這些產品可能會影響全球人們的生活。」
Yu received his doctorate in chemistry from the University of Cambridge in 1999. He subsequently held positions as a postdoctoral fellow at Harvard University and as a junior faculty member at Cambridge and Brandeis University. He joined the faculty at Scripps Research in 2007, where he is the Frank and Bertha Hupp Professor of Chemistry.
余先生於 1999 年在劍橋大學取得化學博士學位。隨後，他在哈佛大學擔任博士後研究員，以及劍橋大學和布蘭戴斯大學的初級教師職位。他加入了斯克里普斯研究的教師 2007, 在那裡，他是弗蘭克和伯塔 Hupp 化學教授.
In 2016, he was named a MacArthur Fellow for pioneering new methods in chemistry and enabling the development of versatile, novel and beneficial chemical compounds. His work was cited by the MacArthur Foundation as “breaking down barriers to the development of versatile compounds with enormous benefits to academic, industrial, and pharmaceutical research.”
2016 年，他被任命為麥克阿瑟研究員，以開創新化學方法，並促進多功能，新穎和有益的化學化合物的開發。麥克阿瑟基金會（MacArthur Foundation）引用他的著作為「打破多功能化合物開發的障礙，對學術，工業和製藥研究具有巨大益處」。
Yu’s research team has published more than 200 papers in influential research journals and has forged collaborations with academic and industry leaders around the world. This includes a collaboration with Bristol Myers Squibb researchers to develop a valuable new technique, known as “ligand-accelerated non-directed C–H functionalization,” that has already found application in pharmaceutical chemistry and a wide range of other chemical industries.
Yu 的研究團隊在具有影響力的研究期刊上發表了 200 多篇論文，並與世界各地的學術和業界領袖建立了合作關係。這包括與 Bristol Myers Squibb 研究人員合作開發一種有價值的新技術，稱為「配體加速非定向 C-H 功能化學」，該技術已經在製藥化學和廣泛的其他化學工業中找到了應用。
“I’m honored that Scripps Research has named me to be the Bristol Myers Squibb Endowed Chair in Chemistry,” says Yu. “This support ensures my team has the flexibility and resources to continue to pursue the most interesting and high-impact ideas.”
Yu 表示：「我很榮幸斯克里普斯研究所命名我為布里斯托爾·邁爾斯施貴布化學主席。」「這項支援可確保我的團隊擁有靈活性和資源，可以繼續追求最有趣和最具影響力的想法。」
About Bristol Myers Squibb
關於布里斯托
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook and Instagram .
Celgene and Juno Therapeutics are wholly owned subsidiaries of Bristol-Myers Squibb Company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company.
塞爾金 和 Juno 治療是百時美施貴寶公司的全資子公司。在美國以外的某些國家., 由於當地法律, Celgene 和朱諾治療被稱為, Celgene, 布里斯托爾·邁爾斯施貴布公司和朱諾治療, 布里斯托爾·邁爾斯施貴寶公司.
About Scripps Research
關於斯克里普斯研究
Scripps Research is ranked the most influential institution in the world for its impact on innovation. We expand basic knowledge in the biosciences, and use these fundamental advancements to develop profound innovations that improve wellbeing. Our researchers lead breakthrough studies that address the world’s most pressing health concerns. Our educational and training programs mold talented and committed students and postdocs into the next generation of leading scientists. We are accelerating the creation and delivery of medical breakthroughs to better human health around the globe.
斯克里普斯研究公司因其對創新的影響而被評為世界上最具影響力的機構。我們擴展生物科學的基礎知識，並利用這些基本進步來開發深刻的創新，從而改善身心健康。我們的研究人員領導了突破性研究，解決了世界上最迫切的健康問題。我們的教育和培訓計劃將才華橫溢且敬業的學生和後期博士塑造成下一代頂尖科學家。我們正在加快醫療突破的創建和交付，以實現更好的 人類健康 在全球範圍內。
corporatefinancial-news
企業財經新聞
譯文內容由第三人軟體翻譯。